Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin to Present at the Deutsche Bank Securities Health Care Conference
Dublin, Ireland and Mystic, CT, USA , April 27, 2010 – Amarin Corporation plc (NASDAQ: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present at Deutsche Bank Securities 35th Annual Health Care Conference.The presentation will be made on Monday, May 3, 2010 at 2:50
View HTML
Toggle Summary Amarin to Present at the Cowen and Company Healthcare Conference
DUBLIN and MYSTIC, Conn., March 3 /PRNewswire-FirstCall/ --Amarin Corporation plc (Nasdaq: AMRN - News ) today announced that John F. Thero, Chief Financial Officer, is scheduled to present at Cowen and Company's 30th Annual Healthcare Conference on Wednesday, March 10, 2010 at 8:45 am Eastern
View HTML
Toggle Summary Amarin Appoints Jan Van Heek Non-Executive Director
DUBLIN and MYSTIC, Conn, Feb. 11 -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, is pleased to announce the appointment of Mr. Jan van Heek to its board of directors as a non-executive director.
View HTML
Toggle Summary Amarin To Present at the 12th Annual BIO CEO & Investor Conference
DUBLIN and MYSTIC, Conn., Feb. 2 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN ) today announced that Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the 12th Annual BIO CEO & Investor Conference on Monday, February 8th at 10:30am Eastern Time.
View HTML
Toggle Summary Amarin Provides 2009 Year-End Review To Shareholders
New investors and experienced new team focused on driving Phase 3 clinical development of AMR101 for cardiovascular diseases
View HTML
Toggle Summary Amarin Corporation Announces First Patients Enrolled in Two Phase 3 Clinical Trials Assessing AMR101 for the Treatment of Cardiovascular Disease
-Lowering Triglyceride Levels For At-Risk Patients-
View HTML
Toggle Summary AMARIN CORPORATION APPOINTS INDUSTRY VETERAN JOSEPH ZAKRZEWSKI AS EXECUTIVE CHAIRMAN
-Appointment Reflects Company Focus on Cardiovascular Disease- -Company withdraws European application for Huntington’s Disease-
View HTML
Toggle Summary AMARIN ANNOUNCES NOTICE OF ANNUAL GENERAL MEETING
DUBLIN, Ireland, November 23, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that it has sent to its shareholders a Notice of the Annual General Meeting of the Company, which will be held on December 21, 2009 in Dublin, Ireland. Copies of the Notice, together with the Company’s Annual
View HTML
Toggle Summary AMARIN CORP IS FIRST SMALL BIOPHARMACEUTICAL COMPANY TO JOIN SAFE-BIOPHARMA ASSOCIATION
AMARIN CORP IS FIRST SMALL BIOPHARMACEUTICAL COMPANY TO JOIN SAFE-BIOPHARMA ASSOCIATION Ft. Lee, N.J. (November 11, 2009) – Amarin Corp .(NASDAQ: AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association , the non-profit
View HTML
Toggle Summary AMARIN APPOINTS JOHN F. THERO AS CHIEF FINANCIAL OFFICER
AMARIN APPOINTS JOHN F. THERO AS CHIEF FINANCIAL OFFICER DUBLIN, Ireland, November 6th, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced the appointment of John F. Thero as the Company’s Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and
View HTML
copyright
© 2019, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation